Please use this identifier to cite or link to this item: https://doi.org/10.1371/journal.pone.0116589
Title: Exploring the interaction of SV2A with racetams using homology modelling, molecular dynamics and site-directed mutagenesis
Authors: Lee J.
Daniels V.
Sands Z.A.
Lebon F.
Shi J.
Biggin P.C.
Verma C. 
Keywords: carrier proteins and binding proteins
etiracetam
radioligand
SV2A protein
ucb 30889
unclassified drug
anticonvulsive agent
etiracetam
membrane protein
nerve protein
piracetam
protein binding
SV2A protein, human
amino acid sequence
Article
binding site
controlled study
drug protein binding
drug structure
human
human cell
hydrophobicity
ligand binding
molecular dynamics
nonhuman
protein conformation
radioassay
sequence alignment
sequence analysis
site directed mutagenesis
structural homology
analogs and derivatives
chemistry
genetics
metabolism
molecular genetics
protein secondary structure
sequence homology
Mus
Amino Acid Sequence
Anticonvulsants
Humans
Membrane Glycoproteins
Molecular Dynamics Simulation
Molecular Sequence Data
Mutagenesis, Site-Directed
Nerve Tissue Proteins
Piracetam
Protein Binding
Protein Structure, Secondary
Sequence Homology, Amino Acid
Issue Date: 2015
Citation: Lee J., Daniels V., Sands Z.A., Lebon F., Shi J., Biggin P.C., Verma C. (2015). Exploring the interaction of SV2A with racetams using homology modelling, molecular dynamics and site-directed mutagenesis. PLoS ONE 10 (2) : e0116589. ScholarBank@NUS Repository. https://doi.org/10.1371/journal.pone.0116589
Abstract: The putative Major Facilitator Superfamily (MFS) transporter, SV2A, is the target for levetiracetam (LEV), which is a successful antiepileptic drug. Furthermore, SV2A knock out mice display a severe seizure phenotype and die after a few weeks. Despite this, the mode of action of LEV is not known at the molecular level. It would be extremely desirable to understand this more fully in order to aid the design of improved antiepileptic compounds. Since there is no structure for SV2A, homology modelling can provide insight into the ligandbinding site. However, it is not a trivial process to build such models, since SV2A has low sequence identity to those MFS transporters whose structures are known. A further level of complexity is added by the fact that it is not known which conformational state of the receptor LEV binds to, as multiple conformational states have been inferred by tomography and ligand binding assays or indeed, if binding is exclusive to a single state. Here, we explore models of both the inward and outward facing conformational states of SV2A (according to the alternating access mechanism for MFS transporters). We use a sequence conservation analysis to help guide the homology modelling process and generate the models, which we assess further with Molecular Dynamics (MD). By comparing the MD results in conjunction with docking and simulation of a LEVanalogue used in radioligand binding assays, we were able to suggest further residues that line the binding pocket. These were confirmed experimentally. In particular, mutation of D670 leads to a complete loss of binding. The results shed light on the way LEV analogues may interact with SV2A and may help with the ongoing design of improved antiepileptic compounds. © 2015 Lee et al.
Source Title: PLoS ONE
URI: https://scholarbank.nus.edu.sg/handle/10635/161744
ISSN: 19326203
DOI: 10.1371/journal.pone.0116589
Appears in Collections:Elements
Staff Publications

Show full item record
Files in This Item:
File Description SizeFormatAccess SettingsVersion 
10_1371_journal_pone_0116589.pdf5.77 MBAdobe PDF

OPEN

PublishedView/Download

SCOPUSTM   
Citations

12
checked on May 27, 2020

Page view(s)

73
checked on May 28, 2020

Google ScholarTM

Check

Altmetric


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.